Shanghai Securities News China Securities Network News (reporter Luo Min) Luoxin Pharmaceutical announced that Shandong Luoxin Pharmaceutical Group Co., Ltd., a subsidiary of the company, recently received the "Notice of Approval of Drug Supplement Application" for edaravone injection approved and issued by the State Drug Administration, and the drug passed the consistency evaluation of the quality and efficacy of generic drugs. Edaravone injection is a brain protection agent (free radical scavenger) used to improve neurological symptoms, activities of daily living and dysfunction caused by acute cerebral infarction, and to inhibit the progression of dysfunction caused by amyotrophic lateral sclerosis (ALS).
![From January 2022, zero tariffs will be implemented on the new anti-cancer drug radium chloride injection[fig]](data:image/gif;base64,R0lGODlhAQABAIAAAP///wAAACwAAAAAAQABAAACAkQBADs=)